These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9740164)

  • 1. Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients.
    St Peter WL; Lewis MJ; Macres MG
    Am J Kidney Dis; 1998 Sep; 32(3):470-4. PubMed ID: 9740164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection.
    Frenken LA; van Lier HJ; Jordans JG; Leunissen KM; van Leusen R; Verstappen VM; Koene RA
    Am J Kidney Dis; 1993 Oct; 22(4):553-6. PubMed ID: 8213795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa.
    Frenken LA; van Lier HJ; Koene RA
    Nephrol Dial Transplant; 1994; 9(9):1295-8. PubMed ID: 7816293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.
    Granolleras C; Leskopf W; Shaldon S; Fourcade J
    Clin Nephrol; 1991 Dec; 36(6):294-8. PubMed ID: 1769141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
    Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
    Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of once-weekly epoetin alfa.
    Barre P; Reichel H; Suranyi MG; Barth C
    Clin Nephrol; 2004 Dec; 62(6):440-8. PubMed ID: 15630903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha.
    Ter Wee PM; de Koter Y; van der Veer O; van Vliet MH
    Clin Nephrol; 2009 Sep; 72(3):177-80. PubMed ID: 19761721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
    Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
    Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from i.v. to s.c. epoetin in hemodialysis patients.
    Knauss MD; Walton T; Macon EJ
    Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and efficacy of multidose epoetin beta (Reco-Pen) for subcutaneous administration in patients with anemia due to renal failure.
    Kleophas W; Kult J; Kreusser W; Piper C; Plache H; Wunderle P; Fiegel V; Härtl W;
    Kidney Blood Press Res; 2003; 26(3):192-8. PubMed ID: 12886047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.